The present disclosure is related to compositions and methods for the regulated and controlled expression of proteins.

The present invention relates to viral particles which exhibit self-regulatory or regulatable features.

Compositions and methods for treating cancers containing an oncogenic KRAS mutant.

The present-disclosure provides methods of treating cancer with certain co-activator of activator protein-1 and estrogen receptor (CAPER)-based polypeptides. In certain embodiments, the methods of the-disclosure target only cancerous cells without adversely affecting non-cancerous cells.

The present disclosure provides regulatable biocircuit systems, effector modules and compositions for cancer immunotherapy. Methods for inducing anti-cancer immune responses in a subject are also provided.

Method for preparing and administering human pluripotent stem cells includes preparing human adipose stem cells from a human; epigenetically modifying the human adipose stem cells (hADSC) to yield directly-generated human pluripotent stem cells (dgHPSC); and engineering the dgHPSC to secrete a therapeutic level of insulin. Preparing the human adipose stem cells includes obtaining a lipoaspirate from a human and preparing adipose stem cells from the lipoaspirate. Epigenetically modifying the hADSC includes inducing the hADSC to yield the dgHPSC. Engineering the dgHPSC includes transducing a human estrogen-related receptor gamma (ERRγ) gene into the dgHPSC. Engineering the dgHPSC further includes transducing a human INS gene into the dgHPSC. The dgHPSC transduced with the ERRγ gene and the human INS gene secrete a higher level of insulin compared to the dgHPSC transduced with the ERRγ gene. The engineered dgHPDC are introduced into a human.

The present disclosure provides an in vitro method for preparation of human pluripotent stem cells (HPSCs) from human adipocyte-derived stem cells (ADSCs) without any genetic engineering techniques and without involving any exogenous gene elements, plasmid or transcription factors and the so obtained HPSCs are referred to as directly-generated human pluripotent stem cells (dgHPSCs). The present invention further provides an in vitro method for insulin production from the dgHPSCs by means of single- or co-transduction with human estrogen-related receptor gamma (ERRγ) gene by the lentivirus vector pWPI/ERRγ encoding the human ERRγ gene and/or with human insulin (INS) gene by a lentivirus vector, pWPI/INS encoding the human INS gene, where the insulin secreted by such co-transduced cells is higher than singly transduced cells. The present invention also provides an in vitro method for insulin production in a glucose-concentration responsive manner involving single transduction of the dgHPSCs with the human ERRγ gene.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Provided herein are methods for treating small round cell tumor(s) by administering anti-androgen receptor therapy to a subject. The anti-androgen receptor therapy may comprise an AR antisense oligonucleotide and may be administered in combination with an additional anti-cancer agent.